Introduction & Objective: The prevalence of type 2 diabetes (T2D) in young adults (age <45 years) is increasing. There is limited data on the burden of diabetes-related complications in young-onset type 2 diabetes (YOT2D).

Methods: Adults with the diagnosis of T2D (ICD codes 250.xx and E11.xx; n=352 826) were identified from the Utah Diabetes Database, a subset of the Utah Population Database. The cohort was divided based on age at first diagnosis of T2D: YOT2D were first diagnosed between 18-44 years old and later-onset type 2 diabetes (LOT2D) were first diagnosed at ≥45 years old. Those with missing data (n=296 295) or laboratory data consistent with type 1 diabetes (n=204) were excluded.

Results: Of the 56 327 people with T2D included, 33% (n=13 087) had YOT2D and 77% (n=43 240) had LOT2D. The mean age at first diagnosis was 35±7 years in YOT2D vs 62±10 years in LOT2D. Female sex, ethnic minorities (Hispanics, non-Hispanic Black, Asian, Pacific Islanders, American Indians), and a positive family history of T2D were associated with YOT2D (p<0.001). YOT2D had a higher prevalence of obesity (68% vs 62%, p<0.001) and were more likely to have DKA and hypoglycemia despite similar C-peptide concentrations and insulin use compared to LOT2D. Glycemic control was worse in YOT2D, both at diagnosis (HbA1c 7.8±2.5 vs 7.2±2.0%, p<0.001) and at 5 years follow up (HbA1c 7.6±3.0 vs 7.1 ±4.8%, p<0.001). Risk for advanced hepatic fibrosis, as determined by the APRI score >0.7, were equally high in both groups (6.9% vs 6.6, p=0.36). Similarly, frequencies of retinopathy (10%) and foot ulceration (3%) were no different. Overall, significant proportions of each group had moderately increased albuminuria (urine albumin ≥ 30 mg/g: 36% vs 34%, p<0.003), diabetic nephropathy (13% vs 18%, p<0.001), and diabetic neuropathy (17% vs 24%, p<0.001).

Conclusion: YOT2D is associated with high prevalence of diabetes-related complications. Precision-focused mitigation strategies are needed to decrease excess adverse outcomes in YOT2D.

Disclosure

A. Sharma: None. J.M. Lazaro-Guevara: None. D. Stucki: None. M.G. Pezzolesi: None.

Funding

American Diabetes Association (7-22-JDFPM-04)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.